Biomedical Engineering Reference
In-Depth Information
57. Orton RJ, Adriaens ME, Gormand A, Sturm OE, Kolch W, Gilbert DR (2009) Computational
modelling of cancerous mutations in the EGFR/ERK signalling pathway. BMC Syst Biol
3:100
58. Overall CM, Wrana JL, Sodek J (1989) Independent regulation of collagenase, 72-kDa
progelatinase, and metalloendoproteinase inhibitor expression in human fibroblasts by
transforming growth factor-beta. J Biol Chem 264:1860-1869
59. Park ES, Kim SJ, Kim SW, Yoon SL, Leem SH, Kim SB, Kim SM, Park YY, Cheong JH,
Woo HG et al (2011) Cross-species hybridization of microarrays for studying tumor
transcriptome of brain metastasis. Proc Natl Acad Sci U S A 108:17456-17461
60. Phillips KA, Veenstra DL, Oren E, Lee JK, Sadee W (2001) Potential role of pharmaco-
genomics in reducing adverse drug reactions: a systematic review. JAMA 286:2270-2279
61. Pinkel D, Albertson DG (2005) Array comparative genomic hybridization and its
applications in cancer. Nat Genet 37(Suppl):S11-S17
62. Rhodes DR, Kalyana-Sundaram S, Mahavisno V, Barrette TR, Ghosh D, Chinnaiyan AM
(2005) Mining for regulatory programs in the cancer transcriptome. Nat Genet 37:579-583
63. Ringner M (2008) What is principal component analysis? Nat Biotechnol 26:303-304
64. Rosenbaum E, Hoque MO, Cohen Y, Zahurak M, Eisenberger MA, Epstein JI, Partin AW,
Sidransky D (2005) Promoter hypermethylation as an independent prognostic factor for
relapse in patients with prostate cancer following radical prostatectomy. Clin Cancer Res
Off J Am Assoc Cancer Res 11:8321-8325
65. Rowley JD (1973) Letter: A new consistent chromosomal abnormality in chronic myeloge-
nous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature
243:290-293
66. Rual JF, Venkatesan K, Hao T, Hirozane-Kishikawa T, Dricot A, Li N, Berriz GF, Gibbons
FD, Dreze M, Ayivi-Guedehoussou N et al (2005) Towards a proteome-scale map of the
human protein-protein interaction network. Nature 437:1173-1178
67. Salphati L, Pang J, Plise EG, Lee LB, Olivero AG, Prior WW, Sampath D, Wong S, Zhang X
(2012) Preclinical assessment of the absorption and disposition of the PI3K/mTOR inhibitor
GDC-0980 and prediction of its pharmacokinetics and efficacy in human. Drug Metab Dispos
40(9):1785-96
68. Segal E, Friedman N, Kaminski N, Regev A, Koller D (2005) From signatures to models:
understanding cancer using microarrays. Nat Genet 37(Suppl):S38-S45
69. Segal E, Shapira M, Regev A, Pe'er D, Botstein D, Koller D, Friedman N (2003) Module
networks: identifying regulatory modules and their condition-specific regulators from gene
expression data. Nat Genet 34:166-176
70. Shen L, Kondo Y, Ahmed S, Boumber Y, Konishi K, Guo Y, Chen X, Vilaythong JN, Issa JP
(2007) Drug sensitivity prediction by CpG island methylation profile in the NCI-60 cancer
cell line panel. Cancer Res 67:11335-11343
71. Simeoni M, Magni P, Cammia C, De Nicolao G, Croci V, Pesenti E, Germani M, Poggesi I,
Rocchetti M (2004) Predictive pharmacokinetic-pharmacodynamic modeling of tumor
growth kinetics in xenograft models after administration of anticancer agents. Cancer Res
64:1094-1101
72. Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, Mandelker D, Leary RJ, Ptak
J, Silliman N et al (2006) The consensus coding sequences of human breast and colorectal
cancers. Science 314:268-274
73. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, Fujiwara S, Watanabe
H, Kurashina K, Hatanaka H et al (2007) Identification of the transforming EML4-ALK
fusion gene in non-small-cell lung cancer. Nature 448:561-566
74. Sorger PK, Allerheiligen SRB, Abernethy DR, Altman KL, Brouwer R, Califano A,
D'Argenio DZ, Iyengar R, Jusko WJ, Lalonde R et al (2011) Quantitative and systems
pharmacology in the post-genomic era: new approaches to discovering drugs and understand-
ing therapeutic mechanisms. In: Ward R (ed) An NIH White Paper by the QSP Workshop
Group—October 2011
Search WWH ::




Custom Search